The most notable adverse effects of COX-1 inhibitors in patients are bleeding and gastrointestinal (GI) ulceration, but additionally kidney failure [4,5], while the essential increased risks of myocardial infarction and cardiovascular thrombotic events are associated with selective COX-2 inhibitors [3]. This evidence concerns the gene PTGS1 and myocardial infarction.